TROP-2

T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe

by
T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe

Trastuzumab deruxtecan ( T-DXd , DS-8201 ) has a clinical incidence of interstitial lung disease (ILD) of approximately 10-15%. The mechanism of occurrence is not due to a single factor, but rather an interaction between target-dependent and non-target-dependent pathways. Firstly, the target-dependent mechanism arises from the low expression levels of HER2 in alveolar epithelial cells … Read more

Research Progress of ADC Drugs for Advanced Gastric Cancer Treatment

by
Research Progress of ADC Drugs for Advanced Gastric Cancer Treatment

Abstract:Gastric cancer is a refractory malignant tumor, ranking fifth in incidence and third in mortality worldwide. Despite various treatment options significantly improving the prognosis of advanced gastric cancer (AGC), survival rates remain unsatisfactory. Therefore, the development of new therapeutic drugs is crucial for enhancing long-term efficacy. Antibody-drug conjugates (ADCs) are innovative and effective anti-tumor drugs … Read more

ADC Drug Advances in Non-Small Cell Lung Cancer

by
ADC Drug Advances in Non-Small Cell Lung Cancer

Introduction Despite rapid advancements in targeted therapy for NSCLC (non-small cell lung cancer), there remains an unmet need. This article summarizes the latest progress in targeted therapies for NSCLC involving Her2, Her3, and Trop-2 to inform readers. NSCLC and ADC Whether through targeted therapy or immunotherapy, the number of lung cancer patients benefiting remains limited, … Read more